Essai clinique
Récupéré
Publication
clinicaltrials.gov
SynapDx
(2013).
SynapDx Autism Gene Expression Analysis Study (STORY).
ClinicalTrials.gov.
SynapDx.
- Date de publication
-
2013
- Identifiant
-
NCT01810341
- Auteurs
-
SynapDx
- Source
- ClinicalTrials.gov
- Type de référence
- clinical_trial
- Éditeur
- SynapDx
- Source de métadonnées
- clinicaltrials.gov
Résumé
This study will prospectively enroll approximately 880 children, at least 18 months and less than 60 months of age, who have been referred to a pediatric developmental evaluation center. Enrolled children will have blood drawn for RNA gene expression analysis and optionally for metabolite, lipid and DNA analysis and undergo a clinical evaluation to determine the presence or absence of a diagnosis of ASD. The primary objective of this study is: \- To develop an algorithm to classify blood RNA gene expression patterns to maximize agreement between the classification and a clinical assessment of presence or absence of Autism Spectrum Disorders (ASD). The secondary objectives of this study are: * To develop an algorithm to classify plasma metabolite and/or lipid profiles in such a way as to maximize agreement between the classification and a clinical assessment of presence or absence of ASD. * To prospectively assess the clinical sensitivity and specificity of the plasma metabolite and/or lipid profile classification algorithm in a separate population consisting of children referred to a developmental evaluation clinic for a possible developmental disorder (DD). * To evaluate clinical sensitivity and specificity of various combinations of gene expression signature, metabolite and/or lipid signatures, and presence of ASD-associated genetic variation detected by chromosomal microarray analysis (CMA) or sequencing protein-coding regions of the genome.